谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.
研究兴趣

论文共 74 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
999MO HARE-40: A Phase I/II Trial of Therapeutic HPV Vaccine (BNT113) in Patients with HPV16 Driven Carcinoma
C.H.H. Ottensmeier, E. King,S. Crabb,I. Karydis, D.M. Graham, K. Martin, I. Eberhart,S. Ewings, P. Lee, K. McCann, L. Chudley, L. Berry, J. Dias, R. Das,J. Furlanetto, E. Johnson,J. Setzer, U. Sahin,Ö. Türeci, G. Griffiths
Annals of Oncology (2024)
引用0浏览0引用
0
0
877P Exploratory Efficacy and Translational Results from the Safety Run in of AHEAD-MERIT, a Phase II Trial of First Line Pembrolizumab Plus the Fixed-Antigen Cancer Vaccine BNT113 in Advanced HPV16+ HNSCC
N.F. Saba,K. Klinghammer, E. Castelluci,A.D. Colevas, T. Rutkowski, D. Thurner, U. Müller-Richter, M. Maio, J.S. Grewal, C.H.H. Ottensmeier, J. Dias, H. Yang, R. Das,J. Furlanetto, A-K. Herzfeldt, M-C. Kühnle, A. Ulges, J. Alles,Ö. Türeci, U. Sahin
Annals of Oncology (2024)
引用0浏览0引用
0
0
29P Characterization of T Cell Responses Induced by the Individualized Mrna Neoantigen Vaccine Autogene Cevumeran in Adjuvant Stage II (high Risk)/stage III Colorectal Cancer (CRC) Patients (pts) from the Biomarker Cohort of the Phase II BNT122-01 Trial
M.E. Elez Fernandez, J. Maurel, V. Morris, S. Kopetz, B. Galligan, S. Ali,E. Derhovanessian,K. Unsal-Kacmaz, L. Manning, H. Henn, T. Weisenburger, M. Tonigold, P. Zurek, M. Fierek-Ulbig, A. Cortini, M. Pino Claveria,L. Preussner, F. Mueller,Ö. Türeci, U. Sahin
Annals of Oncology (2024)
引用0浏览0引用
0
0
Preclinical Efficacy and Pharmacokinetics of an RNA-encoded T Cell–engaging Bispecific Antibody Targeting Human Claudin 6
Christiane R. Stadler,Ursula Ellinghaus,Leyla Fischer,Hayat Baehr-Mahmud,Martin Rao,Claudia Lindemann, Anuhar Chaturvedi, Caroline Scharf, Imke Biermann,Bernhard Hebich, Alexandra Malz, Georg Beresin, Georg Falck, Aline Haecker, Astrid Houben,Michael Erdeljan, Kristina Wolf, Maximilian Kullmann, Philip Chang,Ozlem Tuereci,Ugur Sahin
SCIENCE TRANSLATIONAL MEDICINEno. 748 (2024)
引用0浏览0WOSSCIENCE引用
0
0
148P HexaBody-OX40: A Novel Fcγ Receptor Crosslinking-Independent OX40-targeting Antibody, Exhibits Agonistic Activity in Vitro and Antitumor Activity in Vivo
K. Kemper, M. Köhne, M. van der Kroef, K.B.B. Nuermberger, M. Russier, G. Zom, A-L. Krause, P. de Goeje,F. Gieseke, A. Gorlani,A. Muik, L. Guelen,D. Satijn, S. Fellermeier-Kopf,T. Ahmadi,Ö. Türeci,E. Breij,U. Sahin
Immuno-Oncology and Technology (2023): 100620
引用0浏览0引用
0
0
155P BNT113 + Pembrolizumab As First-Line Treatment in Patients with Unresectable Recurrent/metastatic HNSCC: Preliminary Safety Data from AHEAD-MERIT
K. Klinghammer,N.F. Saba, E. Castelluci,A.D. Colevas, T. Rutkowski,R. Greil, D. Thurner, U. Müller-Richter,A.M. Di Giacomo, J. Grewal, C.H.H. Ottensmeier, A. Atasoy, S. Shpyro,P. Brück,J. Dias, C. Ganser,Ö. Türeci,U. Sahin
Immuno-oncology technology (2022): 100267-100267
引用1浏览0引用
1
0
175P Safety and preliminary efficacy of GEN1042 (DuoBody-CD40x4-1BB) combination therapy in patients with advanced solid tumors
I. Melero, E. Grande Pulido,M.J. De Miguel Luken, M.L. Johnson,J.R. Bauman,V. Moreno Garcia, A.O. Walter, H. Adams,Ö. Türeci, G. Russo,U. Sahin, J. Steinberg,T. Ahmadi, E. Felip
Immuno-Oncology and Technology (2022)
引用0浏览0引用
0
0
加载更多
作者统计

#Papers: 75

#Citation: 8082

H-Index: 31

G-Index: 45

Sociability: 7

Diversity: 3

Activity: 25

  • 合作者
  • 学生
  • 导师
暂无相似学者，你可以通过学者研究领域进行搜索筛选
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn